Research on the Function of Epigenetic Regulation in the Inflammation of Non-alcoholic Fatty Liver Disease

Overview

Journal Life Med

Date 2025 Jan 28

PMID 39872862

Authors

Lin Sun

Zhensheng Yue

Lin Wang

Affiliations

Soon will be listed here.

Abstract

Nonalcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver condition, characterized by a spectrum that progresses from simple hepatic steatosis to nonalcoholic steatohepatitis, which may eventually lead to cirrhosis and hepatocellular carcinoma. The precise pathogenic mechanisms underlying NAFLD and its related metabolic disturbances remain elusive. Epigenetic modifications, which entail stable transcriptional changes without altering the DNA sequence, are increasingly recognized as pivotal. The principal forms of epigenetic modifications include DNA methylation, histone modifications, chromatin remodeling, and noncoding RNAs. These alterations participate in the regulation of hepatic lipid metabolism, insulin resistance, mitochondrial injury, oxidative stress response, and release of inflammatory cytokines, all of which are associated with the onset and progression of NAFLD. This review discussed recent advances in understanding the potential epigenetic regulation of inflammation in NAFLD. Unraveling these epigenetic mechanisms may facilitate the identification of early diagnostic biomarkers and the development of targeted therapeutic strategies for NAFLD.

References

Eslam M, Valenti L, Romeo S . Genetics and epigenetics of NAFLD and NASH: Clinical impact. J Hepatol. 2017; 68(2):268-279. DOI: 10.1016/j.jhep.2017.09.003. View

Ashraf N, Altaf M . Epigenetics: An emerging field in the pathogenesis of nonalcoholic fatty liver disease. Mutat Res Rev Mutat Res. 2018; 778:1-12. DOI: 10.1016/j.mrrev.2018.07.002. View

Wu Y, Lin Z, Li C, Lin X, Shan S, Guo B . Epigenetic regulation in metabolic diseases: mechanisms and advances in clinical study. Signal Transduct Target Ther. 2023; 8(1):98. PMC: 9981733. DOI: 10.1038/s41392-023-01333-7. View

Yang Z, Zhang S, Liu X, Shu R, Shi W, Qu W . Histone demethylase KDM1A promotes hepatic steatosis and inflammation by increasing chromatin accessibility in NAFLD. J Lipid Res. 2024; 65(3):100513. PMC: 10907224. DOI: 10.1016/j.jlr.2024.100513. View

Lao Y, Li Q, Li N, Liu H, Liu K, Jiang G . Long noncoding RNA ENST00000455974 plays an oncogenic role through up-regulating JAG2 in human DNA mismatch repair-proficient colon cancer. Biochem Biophys Res Commun. 2018; 508(2):339-347. DOI: 10.1016/j.bbrc.2018.11.088. View

Pirola C, Fernandez Gianotti T, Burgueno A, Rey-Funes M, Loidl C, Mallardi P . Epigenetic modification of liver mitochondrial DNA is associated with histological severity of nonalcoholic fatty liver disease. Gut. 2012; 62(9):1356-63. DOI: 10.1136/gutjnl-2012-302962. View

Yin Q, Li Y, Zhou Z, Li X, Li M, Liu C . RPA1 controls chromatin architecture and maintains lipid metabolic homeostasis. Cell Rep. 2022; 40(2):111071. DOI: 10.1016/j.celrep.2022.111071. View

Ekstedt M, Hagstrom H, Nasr P, Fredrikson M, Stal P, Kechagias S . Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2014; 61(5):1547-54. DOI: 10.1002/hep.27368. View

Eguchi A, Yan R, Pan S, Wu R, Kim J, Chen Y . Comprehensive characterization of hepatocyte-derived extracellular vesicles identifies direct miRNA-based regulation of hepatic stellate cells and DAMP-based hepatic macrophage IL-1β and IL-17 upregulation in alcoholic hepatitis mice. J Mol Med (Berl). 2020; 98(7):1021-1034. PMC: 7810220. DOI: 10.1007/s00109-020-01926-7. View

10.

Wong V, Chitturi S, Wong G, Yu J, Chan H, Farrell G . Pathogenesis and novel treatment options for non-alcoholic steatohepatitis. Lancet Gastroenterol Hepatol. 2017; 1(1):56-67. DOI: 10.1016/S2468-1253(16)30011-5. View

11.

Gao B, Bataller R . Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology. 2011; 141(5):1572-85. PMC: 3214974. DOI: 10.1053/j.gastro.2011.09.002. View

12.

Sookoian S, Rosselli M, Gemma C, Burgueno A, Fernandez Gianotti T, Castano G . Epigenetic regulation of insulin resistance in nonalcoholic fatty liver disease: impact of liver methylation of the peroxisome proliferator-activated receptor γ coactivator 1α promoter. Hepatology. 2010; 52(6):1992-2000. DOI: 10.1002/hep.23927. View

13.

Jonas W, Schurmann A . Genetic and epigenetic factors determining NAFLD risk. Mol Metab. 2020; 50:101111. PMC: 8324682. DOI: 10.1016/j.molmet.2020.101111. View

14.

Chen G, Broseus J, Hergalant S, Donnart A, Chevalier C, Bolanos-Jimenez F . Identification of master genes involved in liver key functions through transcriptomics and epigenomics of methyl donor deficiency in rat: relevance to nonalcoholic liver disease. Mol Nutr Food Res. 2014; 59(2):293-302. DOI: 10.1002/mnfr.201400483. View

15.

Arguello G, Balboa E, Arrese M, Zanlungo S . Recent insights on the role of cholesterol in non-alcoholic fatty liver disease. Biochim Biophys Acta. 2015; 1852(9):1765-78. DOI: 10.1016/j.bbadis.2015.05.015. View

16.

DiStefano J, Gerhard G . Long Noncoding RNAs and Human Liver Disease. Annu Rev Pathol. 2021; 17:1-21. PMC: 9183788. DOI: 10.1146/annurev-pathol-042320-115255. View

17.

Younossi Z . Non-alcoholic fatty liver disease - A global public health perspective. J Hepatol. 2018; 70(3):531-544. DOI: 10.1016/j.jhep.2018.10.033. View

18.

Qin Y, Li B, Arumugam S, Lu Q, Mankash S, Li J . mA mRNA methylation-directed myeloid cell activation controls progression of NAFLD and obesity. Cell Rep. 2021; 37(6):109968. PMC: 8667589. DOI: 10.1016/j.celrep.2021.109968. View

19.

Cai J, Zhang X, Li H . Role of Innate Immune Signaling in Non-Alcoholic Fatty Liver Disease. Trends Endocrinol Metab. 2018; 29(10):712-722. DOI: 10.1016/j.tem.2018.08.003. View

20.

Hardy T, Zeybel M, Day C, Dipper C, Masson S, McPherson S . Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease. Gut. 2016; 66(7):1321-1328. PMC: 5031527. DOI: 10.1136/gutjnl-2016-311526. View